Replimune Group (Replimune Group) Total Assets

: $532.93 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Replimune Group's Total Assets for the quarter that ended in Dec. 2023 was $532.93 Mil.

During the past 12 months, Replimune Group's average Total Assets Growth Rate was 7.10% per year. During the past 3 years, the average Total Assets Growth Rate was -1.20% per year. During the past 5 years, the average Total Assets Growth Rate was 67.20% per year.

During the past 7 years, Replimune Group's highest 3-Year average Total Assets Growth Rate was 208.80%. The lowest was -1.20%. And the median was 107.25%.

Total Assets is connected with ROA %. Replimune Group's annualized ROA % for the quarter that ended in Dec. 2023 was -37.34%. Total Assets is also linked to Revenue through Asset Turnover. Replimune Group's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Replimune Group Total Assets Historical Data

The historical data trend for Replimune Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Assets

154.33

234.10

543.10

461.19

646.59

Replimune Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets																678.55	646.59	603.89	562.40	532.93

Replimune Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Replimune Group's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets	=	Total Equity (A: Mar. 2023 )	+	Total Liabilities (A: Mar. 2023 )
	=	555.292	+	91.299
	=	646.59

Replimune Group's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	421.537	+	111.393
	=	532.93

Replimune Group (NAS:REPL) Total Assets Explanation

Total Assets is connected with ROA %.

Replimune Group's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-204.48	/	( (562.398	+	532.93)	/ 2 )
	=	-204.48	/	547.664
	=	-37.34 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Replimune Group's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (562.398	+	532.93)	/ 2 )
=	0	/	547.664
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Replimune Group Total Assets Related Terms

Thank you for viewing the detailed overview of Replimune Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group (Replimune Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

7R8:Germany

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Executives

Christopher Sarchi	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos	officer: Chief Medical Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito	officer: Chief Business Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman	officer: Chief Accounting Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke	director, 10 percent owner, officer: Executive Chairman	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin	director, 10 percent owner, officer: President and C.E.O.	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin	10 percent owner, officer: Chief Operating Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi	officer: Chief Financial Officer	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139